Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Combination therapy for the treatment and prevention of hepatic encephalopathy.

Mohammad RA, Regal RE, Alaniz C.

Ann Pharmacother. 2012 Nov;46(11):1559-63. doi: 10.1345/aph.1R146. Epub 2012 Oct 23. Review.

PMID:
23092866
2.

Management of hepatic encephalopathy in the hospital.

Leise MD, Poterucha JJ, Kamath PS, Kim WR.

Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8. Review.

3.

Rifaximin for treatment of hepatic encephalopathy.

Maclayton DO, Eaton-Maxwell A.

Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Epub 2008 Dec 17. Review.

PMID:
19092143
4.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
5.

Disaccharides in the treatment of hepatic encephalopathy.

Sharma P, Sharma BC.

Metab Brain Dis. 2013 Jun;28(2):313-20. doi: 10.1007/s11011-013-9392-4. Epub 2013 Mar 2. Review.

PMID:
23456517
6.

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM.

Yonsei Med J. 2005 Jun 30;46(3):399-407.

7.

Pharmacotherapy for hepatic encephalopathy.

Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A.

Drugs. 2010 Jun 18;70(9):1131-48. doi: 10.2165/10898630-000000000-00000. Review.

PMID:
20518580
8.

Nonabsorbable disaccharides for hepatic encephalopathy.

Als-Nielsen B, Gluud LL, Gluud C.

Cochrane Database Syst Rev. 2004;(2):CD003044. Review.

PMID:
15106187
9.

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.

Huang E, Esrailian E, Spiegel BM.

Aliment Pharmacol Ther. 2007 Oct 15;26(8):1147-61.

10.

Rifaximin for the treatment of hepatic encephalopathy.

de Melo RT, Charneski L, Hilas O.

Am J Health Syst Pharm. 2008 May 1;65(9):818-22. doi: 10.2146/ajhp070298. Review.

PMID:
18436728
11.

Rifaximin for the treatment of hepatic encephalopathy.

Lawrence KR, Klee JA.

Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. Review.

PMID:
18657018
12.

Hepatic encephalopathy: pathophysiology and emerging therapies.

Sundaram V, Shaikh OS.

Med Clin North Am. 2009 Jul;93(4):819-36, vii. doi: 10.1016/j.mcna.2009.03.009. Review.

PMID:
19577116
13.
14.

Update on management of patients with overt hepatic encephalopathy.

Chacko KR, Sigal SH.

Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Review.

PMID:
23948621
15.

Current and emerging strategies for treating hepatic encephalopathy.

Foster KJ, Lin S, Turck CJ.

Crit Care Nurs Clin North Am. 2010 Sep;22(3):341-50. doi: 10.1016/j.ccell.2010.04.007. Review.

PMID:
20691385
16.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
17.

Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H.

Metab Brain Dis. 2013 Jun;28(2):221-5. doi: 10.1007/s11011-012-9372-0. Epub 2012 Dec 29. Review.

PMID:
23275147
18.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

19.

Durability of rifaximin response in hepatic encephalopathy.

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2012 Feb;46(2):168-71. doi: 10.1097/MCG.0b013e318231faae.

PMID:
22011586
20.

Rifaximin for the treatment of hepatic encephalopathy.

Mantry PS, Munsaf S.

Transplant Proc. 2010 Dec;42(10):4543-7. doi: 10.1016/j.transproceed.2010.09.173.

PMID:
21168733
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk